ARTEMIS MED SERVICE Latest Share Price (ARTEMISMED)
TODAY IN ONE LINE
ARTEMISMED fell 1.1% on above-average volume (2.6x avg), in line with Nifty's -0.3% move.
With a market cap of ₹5,458.4 Cr., it trades at a P/E of 46.34. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
ARTEMIS MED SERVICE flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Earnings GrowthEPS (TTM) grew by a solid 28.7% YoY
- ●Healthy Operating MarginsOPM is structurally strong at 15.4%
- ●High Promoter HoldingPromoters hold 58.4% skin-in-the-game
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.24x
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
No red flags identified
Latest ARTEMIS MED SERVICE News
What changed recently?
Recent events, corporate actions, and announcements.
ARTEMIS MED SERVICE valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for ARTEMIS MED SERVICE, framed against the sector median so the premium or discount is obvious at a glance.
ARTEMIS MED SERVICE trades at a P/E of 46.34× and P/B of 5.84×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
ARTEMIS MED SERVICE technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for ARTEMIS MED SERVICE — derived from the latest tape, not yesterday's close.
ARTEMIS MED SERVICE last traded at ₹344.9 with an intraday range of ₹339.7–₹351.8 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹344.90| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 375.43 | +30.53 | +8.85% |
| R3 | 363.33 | +18.43 | +5.34% |
| R2 | 357.57 | +12.67 | +3.67% |
| R1 | 351.23 | +6.33 | +1.84% |
| PIVOT | 345.47 | 0.57 | 0.16% |
| CURRENT | 344.90 | — | — |
| S1 | 339.13 | -5.77 | -1.67% |
| S2 | 333.37 | -11.53 | -3.34% |
| S3 | 327.03 | -17.87 | -5.18% |
| S4 | 314.93 | -29.97 | -8.69% |
ARTEMISMED is trading Below CPR, indicating Bearishness
CPR is Average
Day's range: ₹342.45–₹351.65
Trading Inside opening range
ARTEMIS MED SERVICE financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for ARTEMIS MED SERVICE — consolidated or standalone — with margins, YoY growth and key ratios inline.
ARTEMIS MED SERVICE reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹5,458.4 Cr. and reported EPS of ₹1.98.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 937 | 1,081 ▲ 15.4% |
| Sales Growth YoY %Derived | 6.64% | 15.40% |
| Other Income | 33 | 30 ▼ 9.6% |
| Total Income | 970 | 1,111 ▲ 14.6% |
| 227 | 254 ▲ 11.6% | |
| Gross ProfitDerived | 709 | 827 ▲ 16.6% |
| Gross Margin %Derived | 75.72% | 76.52% |
| 558 | 639 ▲ 14.6% | |
| EBITDA (Operating Profit)Derived | 152 | 188 ▲ 24.0% |
| OPM %Derived | 16.20% | 17.40% |
| 77 | 73 ▼ 5.7% | |
| Profit Before Tax (PBT) | 108 | 139 ▲ 29.3% |
| 25 | 35 ▲ 39.1% | |
| Effective Tax %Derived | 23.67% | 25.48% |
| Total Profit for Period | 82 | 104 ▲ 26.2% |
| Less: Non-controlling Interests | -0 | 0 ▲ 121.4% |
| Net Profit (Owner's PAT)Derived | 83 | 104 ▲ 25.4% |
| Net Profit Margin %Derived | 8.82% | 9.58% |
| PAT Growth YoY %Derived | 68.14% | 25.41% |
| Earnings Per Share (EPS ₹) | 6.00 | 6.55 ▲ 9.2% |
| Diluted Shares Outstanding (Cr) | 14 | 16 ▲ 15.0% |
| Other Comprehensive Income (Net of Tax) | -0 | -0 ▼ 83.4% |
| Total Expenses (incl. D&A & Interest) | 862 | 972 ▲ 12.7% |
| Material Cost % of RevenueDerived | 24.28% | 23.48% |
| Employee Cost % of RevenueDerived | 15.84% | 15.36% |
| Other Cost % of RevenueDerived | 43.69% | 43.76% |
| Interest Coverage (x)Derived | 3.34x | 5.06x |
| Period | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 565 | 408 ▼ 27.7% | 555 ▲ 35.8% | 737 ▲ 32.9% | 879 ▲ 19.1% | 937 ▲ 6.6% | 1,081 ▲ 15.4% | |
| Sales Growth YoY %Derived | — | -27.72% | 35.85% | 32.92% | 19.14% | 6.64% | 15.40% | |
| Other Income | 5 | 4 ▼ 23.0% | 4 ▲ 10.2% | 7 ▲ 88.2% | 7 ▲ 0.2% | 33 ▲ 348.5% | 30 ▼ 9.6% | |
| Total Income | 570 | 412 ▼ 27.7% | 559 ▲ 35.6% | 745 ▲ 33.3% | 886 ▲ 19.0% | 970 ▲ 9.5% | 1,111 ▲ 14.6% | |
139 | 116 ▼ 16.2% | 342 ▲ 193.5% | 195 ▼ 43.0% | 219 ▲ 12.2% | 227 ▲ 4.0% | 254 ▲ 11.6% | ||
| Gross ProfitDerived | 426 | 292 ▼ 31.5% | 213 ▼ 27.0% | 543 ▲ 154.7% | 660 ▲ 21.6% | 709 ▲ 7.5% | 827 ▲ 16.6% | |
| Gross Margin %Derived | 75.42% | 71.49% | 38.40% | 73.57% | 75.11% | 75.72% | 76.52% | |
365 | 257 ▼ 29.6% | 146 ▼ 43.3% | 449 ▲ 208.2% | 527 ▲ 17.5% | 558 ▲ 5.8% | 639 ▲ 14.6% | ||
| EBITDA (Operating Profit)Derived | 61 | 35 ▼ 42.7% | 67 ▲ 91.6% | 94 ▲ 39.3% | 133 ▲ 41.3% | 152 ▲ 14.4% | 188 ▲ 24.0% | |
| OPM %Derived | 10.88% | 8.62% | 12.16% | 12.74% | 15.10% | 16.20% | 17.40% | |
35 | 38 ▲ 6.3% | 34 ▼ 9.3% | 51 ▲ 48.3% | 72 ▲ 41.3% | 77 ▲ 7.7% | 73 ▼ 5.7% | ||
| Profit Before Tax (PBT) | 31 | 8 ▼ 75.4% | 37 ▲ 393.8% | 51 ▲ 36.1% | 68 ▲ 35.3% | 108 ▲ 57.3% | 139 ▲ 29.3% | |
11 | 1 ▼ 87.7% | 6 ▲ 322.1% | 13 ▲ 117.8% | 19 ▲ 53.3% | 25 ▲ 32.0% | 35 ▲ 39.1% | ||
| Effective Tax %Derived | 36.47% | 18.20% | 15.55% | 24.89% | 28.21% | 23.67% | 25.48% | |
| Total Profit for Period | 19 | 6 ▼ 68.3% | 31 ▲ 409.8% | 38 ▲ 21.0% | 49 ▲ 29.3% | 82 ▲ 67.2% | 104 ▲ 26.2% | |
| Less: Non-controlling Interests | -0 | — ▲ 100.0% | -0 | -1 ▼ 42.0% | 0 ▲ 100.7% | -0 ▼ 11065.9% | 0 ▲ 121.4% | |
| Net Profit (Owner's PAT)Derived | 20 | 6 ▼ 68.9% | 32 ▲ 416.5% | 39 ▲ 21.3% | 49 ▲ 27.3% | 83 ▲ 68.1% | 104 ▲ 25.4% | |
| Net Profit Margin %Derived | 3.50% | 1.51% | 5.73% | 5.23% | 5.59% | 8.82% | 9.58% | |
| PAT Growth YoY %Derived | — | -68.88% | 416.47% | 21.32% | 27.32% | 68.14% | 25.41% | |
| Earnings Per Share (EPS ₹) | 1.50 | 0.47 ▼ 68.7% | 2.40 ▲ 410.6% | 2.88 ▲ 20.0% | 3.62 ▲ 25.7% | 6.00 ▲ 65.7% | 6.55 ▲ 9.2% | |
| Diluted Shares Outstanding (Cr) | 13 | 13 ▲ 0.0% | 13 ▲ 0.0% | 13 ▲ 1.3% | 14 ▲ 1.3% | 14 ▲ 1.3% | 16 ▲ 15.0% | |
| Other Comprehensive Income (Net of Tax) | -0 | 0 ▲ 2896.4% | -0 ▼ 171.2% | 1 ▲ 375.2% | -0 ▼ 118.7% | -0 ▲ 42.8% | -0 ▼ 83.4% | |
| Total Expenses (incl. D&A & Interest) | 539 | 404 ▼ 25.0% | 522 ▲ 29.0% | 694 ▲ 33.1% | 817 ▲ 17.8% | 862 ▲ 5.5% | 972 ▲ 12.7% | |
| Material Cost % of RevenueDerived | 25.00% | 28.13% | 61.56% | 26.43% | 24.89% | 24.28% | 23.48% | |
| Employee Cost % of RevenueDerived | 18.30% | 20.57% | 18.80% | 16.38% | 15.81% | 15.84% | 15.36% | |
| Other Cost % of RevenueDerived | 46.24% | 42.30% | 7.44% | 44.46% | 44.19% | 43.69% | 43.76% | |
| Interest Coverage (x)Derived | 3.03x | 1.06x | 3.78x | 3.20x | 2.95x | 3.34x | 5.06x |
ARTEMIS MED SERVICE segment analysis : revenue and profit mix.
Disclosed business segments at ARTEMIS MED SERVICE with their share of revenue and profit, switchable between consolidated and standalone reporting.
ARTEMIS MED SERVICE discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for ARTEMIS MED SERVICE.
Our AI distills the core fundamental drivers supporting ARTEMIS MED SERVICE, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
ARTEMIS MED SERVICE's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Latest quarterly EPS grew 28.7% TTM, demonstrating robust earnings momentum.
Operating margin 13.85% outpaces Apollo 11.13%, signaling superior operational efficiency.
Debt-to-equity 0.0024x effectively debt-free; minimal financial leverage risk.
Promoter holding 58.39% indicates strong insider confidence and long-term commitment.
TTM revenue growth 14.1% supports consistent market share expansion trajectory.
Key Risks.
P/E ratio 40.10x elevated versus sector median, suggesting premium valuation.
Minimal dividend yield 0.14% unattractive for income-focused investors.
ROE 11.02% and ROCE 11.01% lag Apollo significantly; room for improvement.
52-week range ₹203.35–₹339.30 shows 64.8% price volatility limiting upside.
Net cash flow negative ₹7.97 Cr signals recent cash burn despite operations.
Flip Conditions.
Valuation risk. a P/E above 60 would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.
Return-quality risk. ROE below 8% would indicate weaker capital compounding.
ARTEMIS MED SERVICE peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — ARTEMIS MED SERVICE is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
ARTEMIS MED SERVICE chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for ARTEMIS MED SERVICE — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
ARTEMIS MED SERVICE delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for ARTEMIS MED SERVICE over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in ARTEMIS MED SERVICE stood at 41.2% of traded volume, against a 20-day average of 48.8%.
ARTEMIS MED SERVICE announcements: results, concalls, ratings, M&A.
Filings ARTEMIS MED SERVICE sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
ARTEMIS MED SERVICE files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 138 documents below.
Analysts/Institutional Investor Meet/Con. Call Updates
Artemis Medicare Services Limited has informed the Exchange about Analysts/ Institutional Investors Conference - September 22, 2026
Analysts/Institutional Investor Meet/Con. Call Updates
Artemis Medicare Services Limited has informed the Exchange about Analysts/ Institutional Investors' Conference - September 3, 2026
Analysts/Institutional Investor Meet/Con. Call Updates
Artemis Medicare Services Limited has informed the Exchange about Transcript of Earnings Conference Call - Q1 FY27
Analysts/Institutional Investor Meet/Con. Call Updates
Artemis Medicare Services Limited has informed the Exchange about Analysts/ Institutional Investors' Conference - August 13, 2026
Analysts/Institutional Investor Meet/Con. Call Updates
Artemis Medicare Services Limited has informed the Exchange about Audio Recording of Earnings Conference Call - Q1 FY27
Investor decks & rating reports.
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
ARTEMIS MED SERVICE dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue ARTEMIS MED SERVICE has declared, sequenced by announce and record date.
ARTEMIS MED SERVICE corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About ARTEMIS MED SERVICE: business, sector, key facts.
What ARTEMIS MED SERVICE does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
ARTEMIS MED SERVICE operates in the Hospital industry under the Healthcare sector, listed as NSE: ARTEMISMED, BSE: 542919.
Artemis Medicare Services Limited is a healthcare provider operating primarily in India, with international expansion. Their core business revolves around the management and operation of multi-specialty hospitals, delivering a comprehensive range of medical services.
The company's flagship facility is Artemis Hospital, a multi-specialty hospital situated in Gurugram, India. This hospital offers a wide spectrum of medical and surgical interventions, catering to both inpatient and outpatient needs. This includes a broad scope of services extending beyond basic medical care.
Beyond direct medical treatment, Artemis provides extensive ancillary services designed to enhance the patient experience and overall healthcare journey. These services encompass billing and insurance assistance, childcare, emotional and support programs, international patient services, translation and record management, nutritional guidance, patient advocacy, pre-admission testing, smoking cessation programs, and executive health checks. They also offer workplace clinics for counseling and various healthcare education and awareness initiatives.
Furthermore, Artemis's service offerings extend to emergency services, first aid and BLS training, and organizational healthcare audits. This diversified approach positions them as a holistic healthcare provider, addressing not only immediate medical needs but also preventative care, patient support, and broader healthcare system optimization.
In summary, Artemis Medicare Services Limited is a vertically integrated healthcare company focused on delivering high-quality medical care and a comprehensive support system. Their business model combines direct patient care with ancillary services aimed at improving the overall patient experience and promoting wellness.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- DR AGARWALS HEALTH CARE L (AGARWALEYE) Share PricePeer
- APOLLO HOSPITALS ENTER L (APOLLOHOSP) Share PricePeer
- ASTER DM QUALITY CARE (ASTERDM) Share PricePeer
- FORTIS HEALTHCARE (FORTIS) Share PricePeer
- GPT HEALTHCARE (GPTHEALTH) Share PricePeer
- Stocks near 52-week high (breakout watch)Screener
- Breakout Trader strategy playbookStrategy
- Other overvalued NSE stocksScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about ARTEMIS MED SERVICE (ARTEMISMED).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of ARTEMIS MED SERVICE (ARTEMISMED)?
The current share price of ARTEMIS MED SERVICE (ARTEMISMED) is ₹344.90. Today, the stock has declined by ₹3.65 (1.05%), trading in a range of ₹339.70 to ₹351.80. The stock opened at ₹348.55 with a trading volume of 3,47,172 shares.
02Is ARTEMIS MED SERVICE stock a good investment for long-term?
ARTEMIS MED SERVICE can be considered for long-term investment based on several factors. The company has a market capitalization of ₹5,458.4 Cr., P/E ratio of 46.34, ROE of 11.03%, and ROCE of 11.07%. The dividend yield stands at 0.13%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of ARTEMIS MED SERVICE stock?
The 52-week high price of ARTEMIS MED SERVICE (ARTEMISMED) is ₹362.00, while the 52-week low is ₹203.35. Currently trading at ₹344.90, the stock is 69.61% above its 52-week low and 4.72% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy ARTEMIS MED SERVICE stock at the current price?
Whether to buy ARTEMIS MED SERVICE stock at ₹344.90 depends on multiple factors. The stock is currently trading with a P/E ratio of 46.34 and P/B ratio of 5.84. Today's performance shows a loss of 1.05%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of ARTEMIS MED SERVICE and when is the next dividend?
ARTEMIS MED SERVICE offers a dividend yield of 0.13%, which means for every ₹100 invested at the current price of ₹344.90, you can expect to receive approximately ₹0.13 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of ARTEMIS MED SERVICE?
ARTEMIS MED SERVICE's key financial metrics include: P/E Ratio: 46.34, P/B Ratio: 5.84, ROE: 11.03%, ROCE: 11.07%, Dividend Yield: 0.13%, EPS: ₹1.98, Book Value: ₹59.42, and Debt-to-Equity: 0.24. The company's market cap stands at ₹5,458.4 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is ARTEMIS MED SERVICE stock performing today in the market?
ARTEMIS MED SERVICE stock opened at ₹348.55 and is currently trading at ₹344.90, showing a decline of ₹3.65 (1.05%). The intraday high is ₹351.80 and low is ₹339.70. The trading volume stands at 3,47,172 shares, indicating moderate market participation today.
08What is the P/E ratio of ARTEMIS MED SERVICE and what does it indicate?
ARTEMIS MED SERVICE has a Price-to-Earnings (P/E) ratio of 46.34, which means investors are willing to pay 46.34 for every ₹1 of earnings. With an EPS of ₹1.98, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about ARTEMIS MED SERVICE (ARTEMISMED) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.